Basics |
Cel-Sci Corporation
CEL-SCI Corp is a biotechnology company. It is engaged in the research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system.
|
IPO Date: |
December 1, 1984 |
Sector: |
Healthcare |
Industry: |
Biotech |
Market Cap: |
$62.9M |
Activated in VL: |
True |
Average Daily Range |
Avg Daily Range: |
$0.20 | 4.97%
|
Avg Daily Range (30 D): |
$0.32 | 3.32%
|
Avg Daily Range (90 D): |
$0.45 | 6.56%
|
Institutional Daily Volume |
Avg Daily Volume: |
.82M |
Avg Daily Volume (30 D): |
.1M |
Avg Daily Volume (90 D): |
.5M |
Trade Size |
Avg Trade Size (Sh.): |
436 |
Avg Trade Size (Sh.) (30 D): |
112 |
Avg Trade Size (Sh.) (90 D): |
110 |
Institutional Trades |
Total Inst.Trades: |
351 |
Avg Inst. Trade: |
$1.44M |
Avg Inst. Trade (30 D): |
$1.32M |
Avg Inst. Trade (90 D): |
$1.32M |
Avg Inst. Trade Volume: |
M |
Avg Inst. Trades (Per Day): |
1 |
Market Closing Trades |
Avg Closing Trade: |
$1.59M |
Avg Closing Trade (30 D): |
$1.32M |
Avg Closing Trade (90 D): |
$1.32M |
Avg Closing Volume: |
5.66K |
|
|
Financials |
|
TTM |
Q3 2025 |
Q2 2025 |
Basic EPS
|
|
|
|
Diluted EPS
|
$5.66
|
$-1.36
|
$-.08
|
Revenue
|
$ .05M
|
$ -.17M
|
$ -.18M
|
Gross Profit
|
$
|
$
|
$
|
Net Income / Loss
|
$ -25.42M
|
$ -5.66M
|
$ -6.57M
|
Operating Income / Loss
|
$ -24.9M
|
$ -5.49M
|
$ -6.39M
|
Cost of Revenue
|
$
|
$
|
$
|
Net Cash Flow
|
$ 1.41M
|
$ -.13M
|
$
|
PE Ratio
|
1.64
|
|
|
Splits |
May 20, 2025:
1:30
|
Jun 15, 2017:
1:25
|
Sep 25, 2013:
1:10
|
|
|
|